This section compares the effect of CTLA-4 blockade on cancer treatment by the antibody ipilimumab and the H11 nanobody. In cancer therapy, two factors play an essential role in generating an effective Anti-CTLA-4 antibody response; one is increasing the expression of CTLA-4 on tumor-associated...
9D9-CP006单克隆抗体能与小鼠CTLA-4(细胞毒性T淋巴细胞抗原-4)反应,CTLA-4也称为CD152。CTLA-4是一种33 kDa的细胞表面受体,由属于免疫球蛋白超家族CD28家族的Ctla4基因编码。CTLA-4在活化的T淋巴细胞和B淋巴细胞上表达。CTLA-4在结构上类似于T细胞共刺激蛋白CD28,两种分子都与B7家族成员B7-1 (CD80)和B7-2...
Ipilimumab, an antibody that blocks cytotoxic T-lymphocyte antigen 4 (CTLA4), was approved by the US Food and Drug Administration for advanced melanoma. However, only a subset of patients benefit, often with delayed radiographic response and at the expense of immune-related toxicity. Biomarker ...
In the management of melanoma, BRAF inhibitors yield fast disease control; however, the duration of response does not last very long. Ipilimumab—an anti-CTLA4 antibody on the other hand—provides longer-lasting results of treatment but achieves less favorable responses. The aim of this study was...
BioXcell InVivoPlus anti-mouse CTLA-4 (CD152)克隆号9D9单克隆抗体能与小鼠CTLA-4(细胞毒性T淋巴细胞抗原-4)反应,CTLA-4也称为CD152。CTLA-4是一种33 kDa的细胞表面受体,由属于免疫球蛋白超家族CD28家族的Ctla4基因编码。CTLA-4在活化的T淋巴细胞和B淋巴细胞上表达。CTLA-4在结构上类似于T细胞共刺激蛋白...
CTLA-4是一种33 kDa的细胞表面受体,由属于免疫球蛋白超家族CD28家族的Ctla4基因编码。CTLA-4在活化的T淋巴细胞和B淋巴细胞上表达。CTLA-4在结构上类似于T细胞共刺激蛋白CD28,两种分子都与B7家族成员B7-1 (CD80)和B7-2 (CD86)结合。在配体结合时,CTLA-4负调节细胞介导的免疫反应。CTLA-4在诱导和/或维持免疫耐...
Anti-CTLA4 and anti-PD1 were administered with a similar schedule of Wang et al. [32]. Animal model Eight-week-old C57black/6J mice were purchased from Charles River (Charles River Laboratories, Milan, Italy). The animals were housed in pathogen-free colony, and experiments were performed ...
14. Ascierto PA, Bono P, Bhatia S, Melero I, Nyakas MS, Svane IM, et al. Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who pro...
Applications: ELISA, FCM Accession: P09793 Overview Catalog No. FMD17210 Species reactivity Mouse Host species Mouse Isotype VHH, mFc Clonality Monoclonal Conjugation Unconjugated Target Cytotoxic T-lymphocyte protein 4, Cytotoxic T-lymphocyte-associated antigen 4, CTLA-4, CD152, Ctla4 ...
TIM-3 can be used in combination with current anti-CTLA4 and/or anti-PD-1 therapies to treat cancers. Fig.1 Mechanism of action for TIM-3 signaling.1 Published Data An increasing number of preclinical studies and clinical studies have indicated that TIM-3 can be a potential target to...